<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03550781</url>
  </required_header>
  <id_info>
    <org_study_id>2018-992</org_study_id>
    <nct_id>NCT03550781</nct_id>
  </id_info>
  <brief_title>Anti-inflammatory Treatment for Inactive Takayasu Arteritis</brief_title>
  <acronym>ATITA</acronym>
  <official_title>Does Inactive Takayasu Arteritis(NIH Criteria) Need Anti-inflammatory Treatment？</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, the traditional disease activity of Takayasu arteritis is mainly based on National
      Institutes of Health criteria and the inactive cases don't need anti-inflammatory treatment.
      However, pathologic findings showed that there was still inflammatory activity in the
      affected vessels, and the follow-up data also found significant lesion progression in some
      inactive cases. Sixty inactive Takayasu arteritis patients will be recruited to determine
      whether these individuals are active by screening new inflammatory markers in this study. New
      inflammatory markers included tumor necrosis
      factor,interleukin-2,interleukin-6,interleukin-8,interleukin-10,high-sensitivity C-reactive
      protein, and 18f-FDG positron emission tomograph. According to new inflammatory markers,
      sixty patients will be divided into two categories: inactive patients (n=20) and active
      patients (n=40). And then, Forty active patients diagnosed by new inflammatory markers will
      be randomly assigned to either anti-inflammatory therapy group or control group. The changes
      of inflammatory activity and lesion progression will be observed during one-year follow up in
      all 60 patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lesion progression</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Progression of previous lesion degree＞20% or new lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lesion progression</measure>
    <time_frame>baseline, 3 months, 6 months, 9 months</time_frame>
    <description>Progression of previous lesion degree＞20% or new lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma concentration of tumor necrosis factor</measure>
    <time_frame>baseline, 3 months, 6 months, 9 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma concentration of interleukin-2</measure>
    <time_frame>baseline, 3 months, 6 months, 9 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma concentration of interleukin-6</measure>
    <time_frame>baseline, 3 months, 6 months, 9 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma concentration of interleukin-8</measure>
    <time_frame>baseline, 3 months, 6 months, 9 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma concentration of interleukin-10</measure>
    <time_frame>baseline, 3 months, 6 months, 9 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma concentration of high-sensitivity C-reactive protein</measure>
    <time_frame>baseline, 3 months, 6 months, 9 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 18F-fluorodeoxyglucose uptake by positron emission tomograph</measure>
    <time_frame>baseline, 3 months, 6 months, 9 months and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Takayasu Arteritis</condition>
  <condition>Anti-Inflammatory Agents</condition>
  <arm_group>
    <arm_group_label>Anti-inflammatory treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisone and/or cyclophosphamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone, cyclophosphamide</intervention_name>
    <description>Prednisone 0.5mg/(kg•d) and/or cyclophosphamide 2mg/kg</description>
    <arm_group_label>Anti-inflammatory treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Takayasu arteritis diagnosed by the American College of Rheumatology 1990 criteria;

          2. Inactive Takayasu arteritis according to National Institutes of Health criteria;

          3. Age ≥ 14 and ≤ 40 years old at the time of informed consent;

          4. Patients or guardian agree to participate in the study.

        Exclusion Criteria:

          1. Active Takayasu arteritis according to National Institutes of Health criteria;

          2. Poor compliance, intolerance to or poor response to hormone therapy;

          3. Allergy to contrast agent;

          4. Renal insufficiency (serum creatinine &gt;133μmol/L), cardiac insufficiency (NYHA
             functional class III and IV) or abnormal liver function (Alanine transaminase ＞1.5
             times upper limit of normal)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiongjing Jiang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiongjing Jiang, MD</last_name>
    <phone>86-1088322385</phone>
    <email>jxj103@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Dong, MD</last_name>
    <phone>+8615810161393</phone>
    <email>donghui666@sina.com</email>
  </overall_contact_backup>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>June 7, 2018</last_update_submitted>
  <last_update_submitted_qc>June 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Xiongjing Jiang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Takayasu Arteritis</keyword>
  <keyword>Anti-Inflammatory Agents</keyword>
  <keyword>Positron Emission Tomography Computed Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Takayasu Arteritis</mesh_term>
    <mesh_term>Aortic Arch Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

